Prognostic Significance of Preoperative Hemoglobin A1c (HbA1c) in Renal Cell Carcinoma
Prospective Cohort Study for the Impact of Preoperative Glycemic Control Status Measured by HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Renal Cell Carcinoma
Sponsor: Seoul National University Hospital
A observational or N/A phase clinical study on Carcinoma, Renal Cell and Hemoglobin A1c Protein, Human, this trial is ongoing. The trial is conducted by Seoul National University Hospital and has accumulated 8 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status
▶ Show 3 earlier versions
-
May 2018 — Jun 2018 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Seoul National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .